Wei Peng Yong

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al. · The Lancet · 2018 · 1.3K citations · Full text

Pembrolizumab Versus Paclitaxel, Gastrointestinal Oncology, Medicine +7

A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets

Niantao Deng, Liang Kee Goh, Hannah Wang et al. · Gut · 2012 · 635 citations · Full text

Single-Cell Atlas of Lineage States, Tumor Microenvironment, and Subtype-Specific Expression Programs in Gastric Cancer

Vikrant Kumar, Kalpana Ramnarayanan, Raghav Sundar et al. · Cancer Discovery · 2021 · 487 citations · Full text

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial

Eric Van Cutsem, Sanne de Haas, Yoon‐Koo Kang et al. · Journal of Clinical Oncology · 2012 · 482 citations

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

Robin Kate Kelley, Bruno Sangro, William Proctor Harris et al. · Journal of Clinical Oncology · 2021 · 427 citations · Full text